Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$197.44 USD

197.44
4,182,372

-0.11 (-0.06%)

Updated Aug 26, 2024 04:00 PM ET

After-Market: $197.40 -0.04 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Zachary Stutler headshot

AbbVie (ABBV) Stock Falls After $63 Billion Allergan Acquisition Announcement

AbbVie announced Tuesday morning its intent to acquire Allergan for $63 billion.

Abbvie Decides to Acquire Allergan

Abbvie Decides to Acquire Allergan

Mark Vickery headshot

AbbVie to Buy Botox-Maker Allergan, Look Ahead to G-20

AbbVie (ABBV) has agreed to purchase Botox maker Allergan (AGN) for roughly $63 billion in cash and stock.

AbbVie Announces Lifting of FDA's Partial Hold on CANOVA Study

AbbVie (ABBV) receives encouraging news as FDA lifts partial clinical hold on a late-stage study evaluating Venclexta in relapsed/refractory multiple myeloma.

Zacks.com featured highlights include: Crocs, Brinker, Shoe Carnival, AbbVie and Criteo

Zacks.com featured highlights include: Crocs, Brinker, Shoe Carnival, AbbVie and Criteo

AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

AbbVie (ABBV) closed at $78.45 in the latest trading session, marking a -0.42% move from the prior day.

Sanghamitra Saha headshot

Forget Bargain Hunting: Tap 5 Stocks With Rising P/E

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval

Novo Nordisk's (NVO) Esperoct gets EU approval for the treatment of adolescents (less-than or equal-to 12 years of age) and adults with haemophilia A.

Sanofi/Regeneron's Asthma Candidate Meets Goal in Study

Sanofi/Regeneron's IL-33 antibody REGN3500 meets primary endpoint in phase II study in asthma. It does not show increased benefit compared to Dupixent.

Top Ranked Income Stocks to Buy for June 21st

Here are four stocks with buy rank and strong income characteristics for investors to consider today, June 21st.

Is AbbVie (ABBV) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Bayer to Invest 5 Billion Euros in Weedkiller Research

Bayer (BAYRY) announces that it will invest 5 billion euros in developing new weedkillers amid lawsuits claiming its glyphosate-based weedkillers cause cancer.

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $78.60, marking a -0.11% move from the previous day.

J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study

J&J's (JNJ) Tremfya meets the primary endpoint in a late stage study that evaluated the efficacy and safety of the drug for treating patients with psoriatic arthritis.

Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz

Novartis (NVS) announces positive data on CML drugs and biosimilar Hyrimoz.

Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Top Ranked Income Stocks to Buy for June 17th

Here are four stocks with buy rank and strong income characteristics for investors to consider today, June 17th.

Zachary Stutler headshot

3 Big Pharma Stocks to Buy Right Now

These big pharma stocks all have a Zacks Rank #2 or better.

Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study

Pfizer's (PFE) study on JAK inhibitor Xeljanz XR demonstrates the efficacy of the medicine when used as a monotherapy without methotrexate.

Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II

Roche's (RHHBY) hematology portfolio gets a boost as FDA approves Polivy for DLBCL, and lymphoma drug, Gazyva, meets goals in a phase II study.

Lilly Announces Tradjenta Cardiovascular Outcome Study Data

Tradjenta leads to fewer events of hypoglycemia and modest weight reduction in type II diabetes patients compared to Sanofi's Amaryl.

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

AbbVie (ABBV) closed at $76.95 in the latest trading session, marking a -0.62% move from the prior day.

Top Ranked Growth Stocks to Buy for June 10th

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, June 10th

AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study

AstraZeneca's (AZN) lymphoma drug, Calquence, meets the primary endpoint and a key secondary one in a phase III study for the first-line treatment of chronic lymphocytic leukaemia.

Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix

Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix